Please assess the completion status of the following clinical trial:

Trial Title: A Study of Chemoradiation Associated With Nimotuzumab as the Treatment of Locally Advanced Esophageal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years;~2. Histological prove of SCC or esophageal adenocarcinoma;~3. T1N1M0, T2N1M0, T3N0M0, T4N0M0, T3N1M0, T4N1M0, qqTqqNM1a stage, according to the TNM system42;~4. Life expectation above 6 months;~5. Inoperable superior, medial, or distal third esophageal cancer, including GE junction tumors, defined as type I and II tumors in the Siewert classification43 (see Appendix B);~6. Performance status 0, 1, or 2, according to the Eastern Cooperative Oncology Group criteria44 (ECOG) (see Appendix C);~7. Creatinine clearance ≥ 60 ml/min, according to the Cockcroft and Gault formula45 (see Appendix D);~8. Adequate body functions, indicated by~   * Creatinine clearance ≥ 60 ml/min;~  * Bilirubin, transaminase, alkaline phosphatase, and gamma-GT \< 1,5 x the upper limit of normal;~  * leucocytes ≥ 3000/μl;~  * granulocytes ≥ 1500/ μl;~  * hemoglobin ≥ 9 g/dl;~  * platelets ≥ 80000/ μl;~9. Adequate calorie ingestion, at the investigator's discretion;~10. He/she must have signed the informed consent form~Exclusion Criteria:~1. Previous or planned treatment of esophageal carcinoma with surgery, radiotherapy, chemotherapy, or antineoplastic biological therapy;~2. Presence of active infection;~3. Knowledge of the presence of HIV seropositivity;~4. Presence of severe comorbidities that, in the investigator's opinion, will put the patient at a significantly higher risk or will damage the protocol compliance;~5. Presence of a significant neurological or psychiatric disease, including dementia and seizures, as per the investigator's judgment;~6. History of malignant neoplasm, except for adequately treated skin basal carcinoma or SCC, and cervical carcinoma in situ;~7. Presence of peripheral neuropathy;~8. Knowledge of the presence of hypersensitivity or allergy to drugs that will be administered in this protocol;~9. History of severe allergic reaction;~10. Pregnancy or lactation;~11. Presence of aerodigestive fistula (trachea and/or bronchia);~12. Evident presence of trachea and/or bronchia infiltration by the tumor;~13. Presence of uncontrolled hypercalcaemia ≥ 2.9 mmol/L (or grade \>1, according to the NCI-CTCAE, version 3.0).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- STANDARD CHEMORADIATION (Type: ACTIVE_COMPARATOR): Cisplatin 75 mg/m2, IV IV doses on D1 of each chemotherapy cycle, for 4 cycles Fluorouracil 1000 mg/m2, IV IV doses in a 24-hour continuous infusion, from D1 to D4 of each chemotherapy cycle, for 4 cycles.~Radiotherapy 50.4 Gy, fractions of 1.8 Gy/day Equivalent to 28 fractions for 5 and a half weeks.
- CHEMORADIATION + NIMOTUZUMAB (Type: EXPERIMENTAL): Nimotuzumab 200 mg, IV weekly IV doses for up to 26 weeks. Cisplatin 75 mg/m2, IV IV dose on D1 of each chemotherapy cycle, for 4 cycles, always after nimotuzumab.~Fluorouracil 1000 mg/m2, IV IV dose in a 24-hour continuous infusion, from D1 to D4 of each chemotherapy cycle, for 4 cycles.~Radiotherapy 50.4 Gy, fractions of 1.8 Gy/day Equivalent to 28 fractions for 5 and a half weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).